192725-39-6

Usage

Uses

Used in Pharmaceutical Industry:
Lopinavir Metabolite M-1 is used as a research compound for the development of antiviral treatments, particularly against COVID-19. Its role as a metabolite of Lopinavir allows researchers to study its potential therapeutic effects and interactions with the virus.
Used in Research and Development:
Lopinavir Metabolite M-1 is used as a research tool in laboratories to investigate the mechanisms of action, pharmacokinetics, and potential applications of Lopinavir and its derivatives in treating viral infections, including COVID-19.
Used in Drug Metabolism Studies:
As a metabolite of Lopinavir, Lopinavir Metabolite M-1 is used in drug metabolism studies to understand the biotransformation processes, clearance rates, and potential drug-drug interactions involving Lopinavir in the body. This information is crucial for optimizing dosing regimens and ensuring the safety and efficacy of the medication.

InChI:InChI=1/C37H46N4O6/c1-24(2)34(41-19-18-32(43)40-37(41)46)36(45)38-29(20-27-14-7-5-8-15-27)22-31(42)30(21-28-16-9-6-10-17-28)39-33(44)23-47-35-25(3)12-11-13-26(35)4/h5-17,24,29-31,34,42H,18-23H2,1-4H3,(H,38,45)(H,39,44)(H,40,43,46)/t29?,30?,31-,34-/m0/s1

Upstream product

• 192725-88-5 (S)-2-(2,4-dioxotetrahydropyrimidin-1-yl)-3-methylbutyric acid tert-butyl ester 
• 192725-87-4 N-(2-carboxamido)ethyl-L-valine t-butyl ester 
• 192725-86-3 N-(2-carbomethoxy)ethyl-L-valine t-butyl ester 
• 13335-71-2 2-(2,6-dimethylphenoxy)acetic acid 
• 13211-31-9 tert-butyl L-valinate 
• 192725-89-6 (S)-2-(2,4-dioxotetrahydropyrimidin-1-yl)-3-methylbutyric acid 
• 192725-49-8 (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-amino-1,6-diphenylhexane 

Downstream Products

• 221553-72-6 (S)-N-{(1S,3S,4S)-1-Benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phenyl-pentyl}-2-(4-hydroxy-2-oxo-tetrahydro-pyrimidin-1-yl)-3-methyl-butyramide 

Relevant academic research and scientific papers

Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea - Synthesis and structure-activity relationships

The HIV protease inhibitor ABT-378 (lopinavir) has a six-member cyclic urea in the P-2 position. A series of analogues in which the six-member cyclic urea is replaced by various heterocycles was synthesized and the structure-activity relationships explored.

Retroviral protease inhibiting compounds

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir)

The HIV protease inhibitor ABT-378 (Lopinavir) is metabolized rapidly and extensively by CYP-3A4 catalyzed oxidation. Three of the major metabolites identified were synthesized and their antiviral (HIV) activities determined.